GlassScriptPhysician profile
Ali S Huda
NPI 1861848533
$7,735.13
in general payments reported to CMS, 2019-2025
40 companies · $2,166 in 2025
The $2,166 reported for 2025 was more than what 84% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91.06 · 2020: $93.34 · 2021: $145 · 2022: $2,232 · 2023: $910 · 2024: $2,098 · 2025: $2,166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,173.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,117.07 | 2022-2025 | Venaseal, Closurefast |
| Imperative Care, INC | $542.46 | 2023-2025 | Symphony Catheter, Prodigy Catheter |
| Stryker Corporation | $449.18 | 2025 | Clottriever Bold Catheter, Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $413.17 | 2024-2025 | Lifevest |
| Abbott Laboratories | $360.31 | 2019-2024 | Diamondback Coronary, Esprit, Dragonfly Opstar |
| Inari Medical, INC. | $356.36 | 2022-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Boehringer Ingelheim Pharmaceuticals, INC. | $308.83 | 2024-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $271.82 | 2024-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $257.20 | 2024-2025 | Wegovy |
| Kestra Medical Technology Services, INC. | $230.40 | 2024-2025 | Assure Wcd |
| United Therapeutics Corporation | $182.24 | 2025 | Tyvaso |
| Alnylam Pharmaceuticals INC. | $178.16 | 2025 | Amvuttra |
| Lilly USA, LLC | $163.19 | 2024 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $161.50 | 2021-2025 | Farxiga |
| American Regent | $150.00 | 2024 | Injectafer |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $142.79 | 2020-2024 | Kengreal |
| Bridgebio Pharma, INC. | $140.68 | 2025 | Attruby |
| Bayer Healthcare Pharmaceuticals INC. | $124.74 | 2024 | |
| Cardiovascular Systems INC. | $120.20 | 2022 | |
| Tactile Systems Technology INC | $118.94 | 2024-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Biotronik INC. | $118.13 | 2023 | |
| Pfizer INC. | $110.48 | 2024-2025 | |
| Angiodynamics, INC. | $102.33 | 2023 | Alphavac |
| Cordis US Corp. | $85.20 | 2024-2025 | Mynx Control, Mynxgrip |
| Kiniksa Pharmaceuticals International, Plc | $76.48 | 2024 | Arcalyst |
| Boston Scientific Corporation | $55.32 | 2022-2025 | Avvigo Guidance System |
| Heartflow, INC. | $50.92 | 2025 | |
| Amgen INC. | $50.91 | 2024-2025 | Repatha, Repatha |
| Actelion Pharmaceuticals US, INC. | $34.61 | 2025 | Opsumit, Uptravi |
| Shockwave Medical, INC | $33.04 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Janssen Pharmaceuticals, INC | $32.87 | 2023-2024 | Xarelto |
| Cvrx, INC. | $30.38 | 2023 | Barostim Neo System |
| Penumbra, INC. | $30.08 | 2025 | Indigo System, Penumbra System |
| Abiomed | $24.60 | 2025 | |
| Daiichi Sankyo INC. | $23.66 | 2024 | Injectafer |
| Recor Medical INC | $22.18 | 2025 | Paradise Ultrasound Renal Denervation System |
| Getinge USA Sales, LLC | $17.83 | 2023 | Cardiosave Hybrid, Type B Plug |
| Kaneka Medical America LLC | $16.25 | 2025 | Apheresis Machine |
| Scpharmaceuticals INC. | $16.05 | 2024 | |
| Merck Sharp & Dohme LLC | $14.57 | 2025 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Huda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.